Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nebivolol - Janssen

Drug Profile

Nebivolol - Janssen

Alternative Names: Bystolic; Lobivon; Nebilet; Nebilox; Nebivolol hydrochloride; R 067555; R 65824; R 67555; Solistar

Latest Information Update: 27 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen L.P.
  • Developer Allergan; Duncan; Forest Laboratories; Janssen; Menarini
  • Class Antihypertensives; Benzopyrans; Ethanolamines; Fluorobenzenes; Heart failure therapies; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic heart failure; Heart failure; Hypertension
  • Discontinued Angina pectoris

Most Recent Events

  • 29 Jan 2019 Kowa Pharmaceuticals America and Allergan agree to commercialise nebivolol in USA for Hypertension
  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2017 Discontinued - Phase-III for Hypertension in USA (PO), because not listed on Allergan pipeline, June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top